Changing the future of Oncology.

About Sutro Biopharma

Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Platform

Precision protein engineering generates superior molecules

Products

3 product candidates in the clinic as a result of research innovations

Partners

Premier collaborations with Bristol Myers Squibb, Merck, EMD Serono and Vaxcyte (formerly known as SutroVax)

People

Great people making excellence happen, every day! 

Technology

Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.

Pipeline

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and cytokine derivatives targeting immuno-oncology pathways.

Partnerships

Recent News

SutroVax Announces Name Change to Vaxcyte

Foster City, Calif., May 21, 2020 – SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel...

read more

Careers

At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference both as individuals and as part of a team.